Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | EDNRA | P25101 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22492109 | 1.00 | AKR1C3 (0.46) | AKR1C3AKR1C1SMN1; SMN2HDAC4SLC6A2 | |
| SCHEMBL22492141 | 0.89 | AKR1C3 (0.43) | AKR1C3AKR1C1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL30434832 | 0.80 | TSHR (0.46) | AKR1C3AKR1C1HDAC4MEN1KMT2A | |
| SCHEMBL25346259 | 0.77 | ALDH1A1 (0.46) | TSHRLMNAL3MBTL1GAAALDH1A1 | |
| SCHEMBL2190081 | 0.76 | L3MBTL1 (0.40) | HDAC4KMT2ACYP2C19LMNAL3MBTL1 | |
| SCHEMBL22492115 | 0.76 | EPHX1 (0.46) | AKR1C3AKR1C1SMN1; SMN2HDAC4SLC6A2 | |
| SCHEMBL22492112 | 0.76 | EPHX1 (0.46) | AKR1C3AKR1C1SMN1; SMN2HDAC4SLC6A2 | |
| SCHEMBL22492114 | 0.76 | EPHX1 (0.46) | AKR1C3AKR1C1SMN1; SMN2HDAC4SLC6A2 | |
| SCHEMBL4171302 | 0.74 | SMN1; SMN2 (0.44) | SMN1; SMN2SLC6A2ADRA1AHTR2BSLC6A3 | |
| SCHEMBL9220859 | 0.74 | SMN1; SMN2 (0.44) | SMN1; SMN2SLC6A2ADRA1AHTR2BSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332472-B2 | Substituted piperidines as inhibitors of ubiquitin specific protease 7 | LES LABORATOIRES SERVIER (FR) | 2022-05-17 | — | — | US | disclosed |
| US-20200407363-A1 | NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | LES LABORATOIRES SERVIER (FR) | 2020-12-31 | — | — | US | disclosed |
| EP-3717482-A1 | NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | Les Laboratoires Servier SAS (FR) | 2020-10-07 | — | — | EP | disclosed |
| CN-111542524-A | Novel piperidinyl derivatives as inhibitors of ubiquitin-specific protease 7 | 法国施维雅药厂 | 2020-08-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332472-B2 | Substituted piperidines as inhibitors of ubiquitin specific protease 7 | USP7, PSMA7, PSMB7 | AKR1C3 3208/4885AKR1C1 3656/4885SMN1; SMN2 2178/4885 |
| US-20200407363-A1 | NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | PSMB7, PSMA7, USP7 | AKR1C3 3210/4885AKR1C1 3748/4885SMN1; SMN2 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.